PLAAT2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL26657	0.45	9/20
SCHEMBL1027805	0.60	6/20
SCHEMBL710419	0.62	5/20
SCHEMBL1622156	0.50	5/20
SCHEMBL694045	0.58	4/20
SCHEMBL553140	0.50	4/20
SCHEMBL1920945	0.47	4/20
SCHEMBL442914	0.46	4/20
SCHEMBL440625	0.57	3/20
SCHEMBL1776	0.56	3/20
SCHEMBL991969	0.55	3/20
SCHEMBL1681600	0.54	3/20
SCHEMBL659686	0.54	3/20
SCHEMBL349314	0.53	3/20
SCHEMBL1154480	0.53	3/20
SCHEMBL1149507	0.52	3/20
SCHEMBL454778	0.51	3/20
SCHEMBL1990535	0.51	3/20
SCHEMBL1858472	0.51	3/20
SCHEMBL2005264	0.51	3/20

Clinical trials — most relevant to PLAAT2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Omega-3 Fatty Acids on the Human Gene Expression	PHASE4	COMPLETED
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT	PHASE2	COMPLETED
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Assessment of Coronary Plaque Composition	PHASE1	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Choline to Improve Malnutrition and Enhance Cognition	nan	RECRUITING
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke	nan	COMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Canola Oil Multicentre Intervention Trial	nan	COMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Psychological and Biological Markers of Refractory Migraine	nan	UNKNOWN
Epidemiology of Atherosclerosis	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism	nan	COMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers	nan	COMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile	nan	WITHDRAWN
Gene Expression in Obesity and Insulin Resistance	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PLAAT2 binder may also engage these)

Protein	Name	Similarity
PLAAT3	Phospholipase A and acyltransferase 3	0.990	landscape →
Q5R611	—	0.987	Q5R611 →
Q8R3U1	—	0.987	Q8R3U1 →
P53817	—	0.979	P53817 →
A0A0R4IY06	—	0.928	A0A0R4IY06 →
PLAAT4	Phospholipase A and acyltransferase 4	0.926	landscape →
D3ZLY0	—	0.918	D3ZLY0 →
Q8R127	—	0.914	Q8R127 →
Q9I8S4	—	0.913	Q9I8S4 →
Q9D020	—	0.913	Q9D020 →
Q6AY30	—	0.911	Q6AY30 →
Q9D0L4	—	0.911	Q9D0L4 →
Q9H0P0	—	0.908	Q9H0P0 →
P50170	—	0.908	P50170 →
O75452	—	0.908	O75452 →
O88451	—	0.908	O88451 →
Q3T067	—	0.907	Q3T067 →
ADCK1	AarF domain-containing protein kinase 1	0.906	landscape →
O54909	—	0.906	O54909 →
FN3K	Fructosamine-3-kinase	0.905	landscape →
Q15526	—	0.905	Q15526 →
Q9ER35	—	0.905	Q9ER35 →
Q8K4Q7	—	0.905	Q8K4Q7 →
Q93V51	—	0.905	Q93V51 →
Q6P4H8	—	0.904	Q6P4H8 →
GLS2	Glutaminase liver isoform, mitochondrial	0.904	landscape →
Q04799	—	0.904	Q04799 →
Q86V88	—	0.903	Q86V88 →
P56965	—	0.903	P56965 →
P14019	—	0.903	P14019 →